🇺🇸 FDA
Pipeline program

CID-103

CASI-CID-103-101

Phase 1 small_molecule completed

Quick answer

CID-103 for Multiple Myeloma is a Phase 1 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
CASI Pharmaceuticals
Indication
Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials